Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 6/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.68 |
| ▸ | KDR | P35968 | 3/20 | 0.66 |
| ▸ | SYK | P43405 | 2/20 | 0.66 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | TYK2 | P29597 | 1/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.66 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.66 |
| ▸ | BTK | Q06187 | 1/20 | 0.66 |
| ▸ | RAF1 | P04049 | 13/20 | 0.57 |
| ▸ | BRAF | P15056 | 13/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869660 | 0.94 | LCK (0.59) | LCKMAPK14KDRSYKJAK3 | |
| SCHEMBL4867316 | 0.90 | SYK (0.60) | LCKMAPK14KDRSYKJAK3 | |
| SCHEMBL4879514 | 0.89 | RAF1 (0.59) | LCKMAPK14KDRSYKJAK3 | |
| SCHEMBL4918694 | 0.88 | SYK (0.65) | LCKMAPK14KDRSYKSRC | |
| SCHEMBL31003528 | 0.86 | LCK (0.68) | LCKMAPK14KDRSYKJAK3 | |
| SCHEMBL5593548 | 0.86 | LCK (0.52) | LCKMAPK14KDRSYKJAK3 | |
| SCHEMBL4869644 | 0.85 | SYK (0.58) | LCKMAPK14KDRSYKJAK3 | |
| SCHEMBL4877616 | 0.85 | SYK (0.54) | LCKMAPK14KDRSYKJAK3 | |
| SCHEMBL4879885 | 0.85 | LCK (0.66) | LCKMAPK14KDRSYKJAK3 | |
| SCHEMBL4880205 | 0.84 | SYK (0.59) | LCKMAPK14KDRSYKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423038-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (A DELAWARE LIMITED LIABILITY CORPORATION) (BM) | 2008-09-09 | — | — | US | claimed |
| US-20080113986-A1 | such as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; N-[4-methyl-3-(8-methyl-2-methylamino-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-morpholin-4-yl-5-trifluoromethyl-benzamide | IRM LLC (BM) | 2008-05-15 | — | — | US | claimed |
| EP-1765820-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-03-28 | — | — | EP | claimed |
| WO-2006002367-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-01-05 | — | — | WO | claimed |
| US-7423038-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (A DELAWARE LIMITED LIABILITY CORPORATION) (BM) | 2008-09-09 | — | — | US | disclosed |
| US-7423038-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (A DELAWARE LIMITED LIABILITY CORPORATION) (BM) | 2008-09-09 | — | — | US | disclosed |
| US-20080113986-A1 | such as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; N-[4-methyl-3-(8-methyl-2-methylamino-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-morpholin-4-yl-5-trifluoromethyl-benzamide | IRM LLC (BM) | 2008-05-15 | — | — | US | disclosed |
| US-20080113986-A1 | such as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; N-[4-methyl-3-(8-methyl-2-methylamino-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-morpholin-4-yl-5-trifluoromethyl-benzamide | IRM LLC (BM) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113986-A1 | such as serine/threonine, fusion, and tyrosine kinase receptors as nerve and fibroblast growth factor; abnormal activation of immune and nervous systems; antiproliferative; N-[4-methyl-3-(8-methyl-2-methylamino-7-oxo-7,8-dihydropteridin-6-yl)-phenyl]-3-morpholin-4-yl-5-trifluoromethyl-benzamide | LCK, FRK, FYN | LCK 1/4885MAPK14 113/4885KDR 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.